MOREPENLAB vs NATCOPHARM: Stock Comparison

Morepen Laboratories Limited vs Natco Pharma Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Natco Pharma Limited is the larger company by market capitalisation. Morepen Laboratories Limited shows faster revenue growth, while Natco Pharma Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Morepen Laboratories Limited and Natco Pharma Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, MOREPENLAB is more favourable on 4 of 13 scored metrics and NATCOPHARM on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
NATCOPHARM is the larger company
₹16,536 Cr vs ₹3,035 Cr
P/E Ratio
NATCOPHARM has a lower P/E
11.68x vs 32.71x
P/B Ratio
NATCOPHARM has a lower P/B
1.8x vs 2.49x
EPS
NATCOPHARM has higher earnings per share
₹79.24 vs ₹1.79
Dividend Yield
NATCOPHARM has a higher dividend yield
0.52% vs 0.33%
Revenue Growth (TTM YoY)
MOREPENLAB has faster revenue growth
4% vs -39.6%
EPS Growth (TTM YoY)
MOREPENLAB has faster EPS growth
-18.9% vs -34.1%
Qtr Sales Growth
MOREPENLAB has stronger quarterly sales growth
4.05% vs -39.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricMOREPENLABNATCOPHARM
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricMOREPENLABNATCOPHARM
Live Price₹55.3₹925.05
Day Change-2.4%-0.22%
Volume30.92 L1.52 L
52-Week High₹64.58₹1,226.8
52-Week Low₹33.05₹789
Distance from 52W High-14.37%-24.6%

Valuation

MetricMOREPENLABNATCOPHARM
Market Cap₹3,035 Cr₹16,536 Cr
P/E Ratio32.71x11.68x
P/B Ratio2.49x1.8x
EPS₹1.79₹79.24
Book Value₹22.17₹514.92
Dividend Yield0.33%0.52%

Growth

MetricMOREPENLABNATCOPHARM
Revenue Growth (TTM YoY)4%-39.6%
EPS Growth (TTM YoY)-18.9%-34.1%
Qtr Sales Growth4.05%-39.5%
Qtr Profit Growth-22.5%-34.1%

Profitability & Leverage

MetricMOREPENLABNATCOPHARM
ROE6.2%16.9%
ROCE8.05%17.1%
Net Margin5.25%34.78%
Operating Margin6.96%35.2%
Debt to Equity0.17x0.08x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricMOREPENLABNATCOPHARM
Promoter Holding35.65%49.14%
FII Holding1.46% 0.12 pp16.99% 0.38 pp
DII Holding1.28% 0.03 pp5.62% 0.16 pp
Public Holding61.59% 0.09 pp27.97% 0.22 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Morepen Laboratories Limited and Natco Pharma Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.